{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:11Z","timestamp":1791412031780,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.065","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T01:47:41Z","timestamp":1651024061000},"page":"3305-3312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance"],"prefix":"10.1016","volume":"40","author":[{"given":"Sharifa","family":"Nasreen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Calzavara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Thampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.065_b0005","unstructured":"Health Canada. Drug and vaccine authorizations for COVID-19: List of applications received: Government of Canada; 2021 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/authorization\/applications.html [accessed 23 November 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0010","unstructured":"Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications: Government of Canada; 2021 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/authorization\/list-drugs.html#wb-auto-4 [accessed 23 November 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0015","unstructured":"Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications Ottawa, ON: Government of Canada; 2021 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/authorization\/list-drugs.html [accessed 19 March 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0020","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots \u2013 vaccine safety surveillance in action Toronto, ON: Queen\u2019s Printer for Ontario; 2021 [Available from: https:\/\/www.publichealthontario.ca\/-\/media\/documents\/ncov\/vaccines\/2021\/07\/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en [accessed 6 June 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0025","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London (UK): Department of Health and Social Care 2021 [Available from: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed, 26 October 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0030","unstructured":"Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report [Internet] Canberra: Department of Health, Australian Government; 2021 [Available from: https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-14-10-2021 [accessed, 26 October 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0035","unstructured":"World Health Organization (WHO). COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines [Internet] Geneva: WHO; 2021 [Available from: https:\/\/www.who.int\/news\/item\/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines [accessed, 14 June 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0040","unstructured":"Gov.il. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). Press release [Internet] Israel: Ministry of Health; 2021 [Available from: https:\/\/www.gov.il\/en\/departments\/news\/01062021-03 [accessed, 26 October 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0045","unstructured":"Shimabukuro T. COVID-19 Vaccine Safety Updates. Vaccines and Related Biological Products. Advisory Committee (VRBPAC). [VRBPAC meeting presentation] [Internet] Atlanta: United States Centers for Disease Control and Prevention (CDC), COVID-19 Vaccine Task Force; 2021 [Available from: https:\/\/www.fda.gov\/media\/150054\/download [accessed, 20 June 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0050","unstructured":"European Medicines Agency (EMA). COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis [Internet] Amsterdam: EMA; 2021 [Available from: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis [accessed, 20 June 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0055","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to October 17, 2021 Toronto, ON: Queen\u2019s Printer for Ontario; 2021 [Available from: https:\/\/www.publichealthontario.ca\/-\/media\/documents\/ncov\/epi\/covid-19-aefi-report.pdf?sc_lang=en [accessed, 26 October 2021]."},{"key":"#cr-split#-10.1016\/j.vaccine.2022.04.065_b0060.1","doi-asserted-by":"crossref","unstructured":"Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021;148","DOI":"10.1542\/peds.2021-052478"},{"key":"#cr-split#-10.1016\/j.vaccine.2022.04.065_b0060.2","doi-asserted-by":"crossref","unstructured":"(3) doi: https:\/\/doi.org\/10.1542\/peds.2021-052478 [published Online First: 2021\/06\/06].","DOI":"10.1542\/peds.2021-052478"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.065_b0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.121.055891","article-title":"Myocarditis Temporally Associated With COVID-19 Vaccination","volume":"144","author":"Rosner","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.065_b0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis With COVID-19 mRNA Vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2022.04.065_b0075","doi-asserted-by":"crossref","unstructured":"Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. medRxiv 2021:2021.12.02.21267156. doi: https:\/\/doi.org\/10.1101\/2021.12.02.21267156.","DOI":"10.1101\/2021.12.02.21267156"},{"key":"10.1016\/j.vaccine.2022.04.065_b0080","doi-asserted-by":"crossref","unstructured":"Abraham N, Spruin S, Rossi T, et al. Myocarditis and\/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines. JVAC-D-21-03106 2021:Available at SSRN: https:\/\/ssrn.com\/abstract=3988612.","DOI":"10.1016\/j.vaccine.2022.05.048"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.065_b0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2022.04.065_b0090","unstructured":"World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines 2021 [Available from: https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs [accessed 10 August, 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0095","unstructured":"European Medicines Agency (EMA). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB Public Statement 2021 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf [accessed 10 August, 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0100","unstructured":"Advisory Committee on Immunization Practices (ACIP). Guillain-Barr\u00e9 Syndrome (GBS) after Janssen COVID-19 Vaccine: Vaccine Adverse Event Reporting System (VAERS). Meeting of the Advisory Committee on Immunization Practices (ACIP), July 22, 2021; 2021."},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.065_b0105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.065_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin Mol Allergy"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.065_b0115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2022.04.065_b0120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.065_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.04.065_b0130","unstructured":"Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document. BNT162B2 [COMIRNATY (COVID-19 VACCINE, MRNA)]: Food and Drug Administration (FDA); 2021 [Available from: https:\/\/www.fda.gov\/media\/153409\/download [accessed, 26 October 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0135","unstructured":"Centers for Disease Control and Prevention (CDC). CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years 2021 [Available from: https:\/\/www.cdc.gov\/media\/releases\/2021\/s1102-PediatricCOVID-19Vaccine.html [accessed 3 November 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0140","unstructured":"Health Canada. Health Canada authorizes use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in children 5 to 11 years of age: Government of Canada; 2021 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/news\/2021\/11\/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html [accessed 19 November 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0145","unstructured":"National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. Ottawa, ON: Government of Canada; 2021 [Available from: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines\/pfizer-biontech-10-mcg-children-5-11-years-age\/pfizer-biontech-10-mcg-children-5-11-years-age.pdf [accessed 19 November 2021]."},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.065_b0150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.vaccine.2014.10.047","article-title":"The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines","volume":"33","author":"Lopalco","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.065_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The Critical Role Background Rates of Possible Adverse Events in the Assessment of COVID-19 Vaccine Safety","author":"Black","year":"2021","journal-title":"Vaccine"},{"issue":"9707","key":"10.1016\/j.vaccine.2022.04.065_b0160","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.065_b0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1471-2458-11-329","article-title":"Estimating background rates of Guillain-Barre Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1\/09 immunization campaign","volume":"11","author":"Deeks","year":"2011","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.065_b0170","article-title":"The Expected Number of Background Disease Events during Mass Immunization in China","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.065_b0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052019","article-title":"Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study","volume":"11","author":"Nasreen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2022.04.065_b0180","doi-asserted-by":"crossref","unstructured":"Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine 2021;39(28):3666\u201377. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.016.","DOI":"10.1016\/j.vaccine.2021.05.016"},{"key":"10.1016\/j.vaccine.2022.04.065_b0185","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.04.065_b0190","unstructured":"International statistical classification of diseases and related health problems, tenth revision, Canada (ICD-10-CA). Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2018."},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.065_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210833","article-title":"Demonstration of background rates of three conditions of interest for vaccine safety surveillance","volume":"14","author":"Wormsbecker","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2022.04.065_b0200","article-title":"Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0)","author":"Willame","year":"2021","journal-title":"Zenodo"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.065_b0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","article-title":"Confidence intervals for directly standardized rates: a method based on the gamma distribution","volume":"16","author":"Fay","year":"1997","journal-title":"Stat Med"},{"issue":"22","key":"10.1016\/j.vaccine.2022.04.065_b0210","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2013-304449","article-title":"The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood","volume":"99","author":"Kyt\u00f6","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.vaccine.2022.04.065_b0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2021.03.019","article-title":"Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007\u20132016","volume":"149","author":"Vasudeva","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vaccine.2022.04.065_b0220","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario respiratory pathogen bulletin [Internet]. Toronto, ON: Queen\u2019s Printer for Ontario; 2021 [Available from: https:\/\/www.publichealthontario.ca\/en\/data-and-analysis\/infectious-disease\/respiratory-pathogens-weekly\/respiratory-pathogens-historical [accessed November 25 2021]."},{"key":"10.1016\/j.vaccine.2022.04.065_b0225","unstructured":"Government of Ontario. Guide to reopening Ontario\u2019s schools: Queen's Printer for Ontario; 2020 [Available from: https:\/\/www.ontario.ca\/page\/guide-reopening-ontarios-schools [accessed November 25 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.065_b0230","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.9778\/cmajo.20200311","article-title":"Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study","volume":"9","author":"Bhatia","year":"2021","journal-title":"CMAJ Open"},{"key":"10.1016\/j.vaccine.2022.04.065_b0235","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5823","article-title":"Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.065_b0240","doi-asserted-by":"crossref","first-page":"e74529","DOI":"10.1371\/journal.pone.0074529","article-title":"Seasonality of Kawasaki disease: a global perspective","volume":"8","author":"Burns","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.065_b0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.pediatrneurol.2015.01.001","article-title":"Diurnal and seasonal occurrence of febrile seizures","volume":"52","author":"Mikkonen","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.vaccine.2022.04.065_b0250","unstructured":"Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study Toronto: Institute for Clinical Evaluative Sciences; 2006 [Available from: https:\/\/www.ices.on.ca\/flip-publication\/canadian-istitute-for-health-information-discharge\/files\/assets\/basic-html\/index.html#9."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:12:38Z","timestamp":1759403558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":51,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22005205"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.065","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.12.22269169","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}